EGFR and adenocarcinoma: Finally, the percentage of adenocarcinomas relative to the adenomas at death was lower in EGFR/MET than EGFR mice (Figure 1C), a feature probably related to their shorter survival with less time to allow tumors to become full-blown carcinomas.